Welcome to our dedicated page for Xilio Therapeutics news (Ticker: XLO), a resource for investors and traders seeking the latest updates and insights on Xilio Therapeutics stock.
Xilio Therapeutics, Inc. (Nasdaq: XLO) is a biopharmaceutical company based in Waltham, Massachusetts, dedicated to pioneering tumor-activated immuno-oncology (I-O) therapies aimed at significantly improving outcomes for cancer patients. The company's name, Xilio, is derived from the Latin term 'ex nihilo,' meaning creation or big bang, symbolizing its innovative approach.
Xilio leverages its proprietary platform to develop a pipeline of novel, tumor-activated clinical and preclinical I-O molecules. These include engineered antibodies, cytokines, and chemokines, all designed to localize anti-tumor activity within the tumor microenvironment, thus optimizing the therapeutic index and minimizing systemic side effects.
Key Products and Developments:
- XTX202: An investigational tumor-activated, engineered IL-2 molecule designed to stimulate CD8+ effector T cells and natural killer (NK) cells without stimulating regulatory T cells. Recent Phase 1/2 data showed a 50% disease control rate at higher doses, and it is currently being evaluated in a Phase 2 trial for melanoma and renal cell carcinoma.
- XTX101: A tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody designed to block CTLA-4 and deplete regulatory T cells within the tumor microenvironment. It is being evaluated in combination with atezolizumab in a Phase 1/2 clinical trial for advanced solid tumors.
- XTX301: An engineered IL-12 molecule designed to boost anti-tumor immunity and convert 'cold' tumors into 'hot' ones. XTX301 is in a Phase 1 clinical trial, and Xilio has recently entered into an exclusive license agreement with Gilead Sciences for its development.
Recent Achievements:
- XTX202 Phase 1 monotherapy dose-escalation success at a dose level of 4.0 mg/kg, with plans to explore combination therapy opportunities.
- The company announced a strategic partnership with Gilead Sciences to accelerate the development of XTX301.
- Financial results indicate that Xilio's existing cash and cash equivalents can fund operations into the second quarter of 2025, bolstered by recent private placements and upfront payments from strategic partnerships.
For more detailed information on Xilio Therapeutics and its pipeline of tumor-activated I-O therapies, visit www.xiliotx.com.
Xilio Therapeutics, a clinical-stage biotechnology firm, has announced the appointment of Dr. Aoife Brennan and Dr. James Shannon to its board of directors as of June 13, 2024.
Dr. Brennan brings over 16 years of industry leadership, having held executive roles at Synlogic and Biogen, while Dr. Shannon has over 30 years of experience, previously serving as chief medical officer at GlaxoSmithKline and holding leadership positions at Novartis.
Their extensive expertise is expected to significantly contribute to Xilio's ongoing development of novel, tumor-activated immuno-oncology therapies, with several clinical milestones anticipated in the near term.
Xilio Therapeutics (NASDAQ: XLO) announced significant pipeline and business updates alongside its Q1 2024 financial results. Highlighting their progress, they plan to initiate a Phase 2 trial for XTX101, an Fc-enhanced anti-CTLA-4, in combination with atezolizumab for MSS CRC in Q3 2024, and report clinical data in Q4 2024. The XTX301 IL-12 program, partnered with Gilead Sciences, received $43.5M upfront and is set for Phase 1 data release in Q4 2024. Furthermore, Xilio's research efforts on bispecifics and immune cell engagers are advancing. Financially, Xilio ended Q1 2024 with $34M in cash, supplemented by an additional $44.6M from Gilead agreements and private placements, projecting a cash runway until Q2 2025.
FAQ
What is the current stock price of Xilio Therapeutics (XLO)?
What is the market cap of Xilio Therapeutics (XLO)?
What is Xilio Therapeutics, Inc.?
What does the name Xilio mean?
What are the key products developed by Xilio?
What is the focus of Xilio's technology platform?
What recent achievements has Xilio reported?
What is XTX202?
What is XTX101?
What is XTX301?
How can I learn more about Xilio Therapeutics?
What are the financial prospects of Xilio Therapeutics?
